TG Therapeutics Hits Day High with Strong 8.03% Intraday Surge

TG Therapeutics, Inc. has experienced significant activity today, with the stock rising by 8.03% and reaching an intraday high of USD 35.07. This notable performance comes amid a backdrop of strong financial metrics, including a remarkable net profit growth of 457.06% reported in June, with the latest quarterly net profit standing at USD 28.35 million, reflecting a 182.49% increase.
The company has also achieved its highest quarterly net sales at USD 141.15 million, showcasing robust operational performance. With an impressive interest coverage ratio and minimal interest costs, TG Therapeutics demonstrates financial stability.

Institutional holdings are notably high at 80.19%, indicating strong backing from investors with substantial analytical resources. Over the past year, the company has generated returns of 38.68%, consistently outperforming the S&P 500 across multiple annual periods.

TG Therapeutics operates within the Pharmaceuticals & Biotechnology industry, boasting a market capitalization of USD 5,139 million and a return on equity of 22.16%. The stock's price-to-earnings ratio stands at 158.00, reflecting its growth potential in the market.